A Multiinstitutional Evaluation of the Analgesic Efficacy and Safety of Ketorolac Tromethamine, Acetaminophen plus Codeine, and Placebo in Cancer Pain
A Multiinstitutional Evaluation of the Analgesic Efficacy and Safety of Ketorolac Tromethamine, Acetaminophen plus Codeine, and Placebo in Cancer Pain
复制标题
酮咯酸氨丁三醇、对乙酰氨基酚加可待因和安慰剂治疗癌性疼痛的镇痛功效和安全性的多机构评估
DOI：
10.1002/j.1875-9114.1990.tb02577.x
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
E. Wolin
中科院分区：
文献类型：
--
作者：
R. Carlson;R. Borrison;Harvey B. Sher;P. Eisenberg;P. Mowry;E. Wolin
75例中重度癌痛患者随机双盲分成3组，分别口服首剂酮咯酸氨丁三醇10 mg、对乙酰氨基酚600 mg加可待因60 mg或安慰剂，随后每日4次口服酮咯酸或对乙酰氨基酚加可待因。治疗组之间的患者特征相似。第一次剂量的观察证明，酮咯酸和对乙酰氨基酚加可待因在癌症疼痛方面产生了同等的减轻作用，从疼痛强度差异和疼痛缓解的角度来看，它们优于安慰剂。多剂量比较证明，在平均每日疼痛缓解方面，扑热息痛加可待因的效果较小，但在统计学上具有显著优势，尽管两种研究药物的平均每日总体效果评级没有差异。不良症状用酮咯酸和对乙酰氨基酚加可待因均可接受。我们得出结论，酮咯酸在癌症疼痛患者中具有显著的止痛活性，尽管它在这些患者的治疗方案中的确切作用仍未确定。(药物疗法1990；第10(3)：211-216页)
Seventy‐five patients with moderate to severe cancer pain were randomly assigned in a double‐blind fashion to receive first‐dose ketorolac tromethamine 10 mg orally, acetaminophen 600 mg plus codeine 60 mg orally, or placebo, followed by subsequent doses of ketorolac or acetaminophen plus codeine four times daily for 7 days. Patient characteristics were similar among the treatment groups. The first‐dose observation documented that both ketorolac and acetaminophen plus codeine produced an equivalent reduction in cancer pain and were superior to placebo as measured by pain intensity differences and pain relief. Multidose comparison documented a small but statistically significant advantage in mean daily pain relief favoring acetaminophen plus codeine, although there were no differences in mean daily ratings of overall effects for either study medication. Adverse symptoms were acceptable with both ketorolac and acetaminophen plus codeine. We conclude that ketorolac has significant analgesic activity in patients with cancer pain, although its precise role in the treatment regimen of these patients remains undefined. (Pharmacotherapy 1990;10(3):211–216)